Boehringer appoints Paul Fonteyne to lead US operations

Boehringer Ingelheim has promoted Paul Fonteyne to president and CEO of its US operations.

He takes over from J Martin Carroll, who will remain with the company in a corporate strategy and development role.

"Change is a necessary and healthy part of any successful company," said Carroll. "After nine years as president and CEO, it was time to let others take the lead on the day-to-day management of the company's US operations.

“I have worked with Paul for more than 15 years, and am confident that his depth and breadth of experience, combined with his passion for finding new ways to bring medicines to patients makes him well-suited to take on this role and help lead the company to even greater success.”

Fonteyne was formerly corporate senior vice president with responsibility for leading the global marketing strategy supporting Boehringer's prescription medicines business.

"I am excited to be given the opportunity to lead the US operations," said Fonteyne. "I believe this company is stronger now than at any point in its 126 year history.

“I look forward to working with my colleagues in the US and globally to bring the best ideas to bear so that we may continue delivering on our commitment to bring more health to patients and their families."